{"id":"https://openalex.org/W3094836633","doi":"https://doi.org/10.1182/blood-2020-140849","title":"Targeting Antibody Checkpoint Fcgriib Using Monoclonal Antibody BI-1206 to Overcome Therapeutic Resistance in Mantle Cell Lymphoma","display_name":"Targeting Antibody Checkpoint Fcgriib Using Monoclonal Antibody BI-1206 to Overcome Therapeutic Resistance in Mantle Cell Lymphoma","publication_year":2020,"publication_date":"2020-11-05","ids":{"openalex":"https://openalex.org/W3094836633","doi":"https://doi.org/10.1182/blood-2020-140849","mag":"3094836633"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-140849","doi":"https://doi.org/10.1182/blood-2020-140849","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-140849","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022585377","display_name":"Alexa A Jordan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexa A Jordan","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083447411","display_name":"Joseph Mitchell McIntosh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph McIntosh","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100355813","display_name":"Yang Liu","orcid":"https://orcid.org/0000-0002-1910-8076","observed_orcids":["https://orcid.org/0000-0002-1910-8076"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yang Liu","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042253574","display_name":"Angela Leeming","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Angela Leeming","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"William Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Lee","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065612884","display_name":"Ingrid Karlsson","orcid":"https://orcid.org/0009-0006-2466-919X","observed_orcids":["https://orcid.org/0009-0006-2466-919X"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Ingrid Karlsson","raw_affiliation_strings":["BioInvent International AB, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioInvent International AB, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108728970","display_name":"Linda M\u00e5rtensson","orcid":"https://orcid.org/0009-0002-9518-7359","observed_orcids":["https://orcid.org/0009-0002-9518-7359"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Linda M\u00e5rtensson","raw_affiliation_strings":["BioInvent International AB, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioInvent International AB, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023906837","display_name":"Mathilda Kovacek","orcid":"https://orcid.org/0009-0002-5156-7261","observed_orcids":["https://orcid.org/0009-0002-5156-7261"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Mathilda Kovacek","raw_affiliation_strings":["BioInvent International AB, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioInvent International AB, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049258782","display_name":"Ingrid Teige","orcid":"https://orcid.org/0009-0007-5996-3396","observed_orcids":["https://orcid.org/0009-0007-5996-3396"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Ingrid Teige","raw_affiliation_strings":["BioInvent International AB, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioInvent International AB, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013771543","display_name":"Bj\u00f6rn Frend\u00e9us","orcid":"https://orcid.org/0000-0003-3177-8686","observed_orcids":["https://orcid.org/0000-0003-3177-8686"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Bj\u00f6rn Frend\u00e9us","raw_affiliation_strings":["BioInvent International AB, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioInvent International AB, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100438316","display_name":"Michael L. Wang","orcid":"https://orcid.org/0000-0001-9748-5486","observed_orcids":["https://orcid.org/0000-0001-9748-5486"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Wang","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110619691","display_name":"Changying Jiang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Changying Changying Jiang","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"136","issue":"Supplement 1","first_page":"35","last_page":"35"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9887999892234802,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9887999892234802,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.009399999864399433,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.996999979019165},{"id":"https://openalex.org/keywords/fcgammariib","display_name":"Fc\u03b3RIIB","score":0.8629999756813049},{"id":"https://openalex.org/keywords/treatment-resistance","display_name":"treatment resistance","score":0.7429999709129333},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.7319999933242798},{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.9909999966621399},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":1.0},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.7649999856948853},{"id":"https://openalex.org/keywords/bcl2-inhibitors","display_name":"BCL-2 inhibitor","score":0.984000027179718},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.7089999914169312},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.40799999237060547},{"id":"https://openalex.org/keywords/antibody-internalization","display_name":"antibody internalization","score":0.5320000052452087},{"id":"https://openalex.org/keywords/fc-gamma-receptor","display_name":"Fc gamma receptor","score":0.5419999957084656},{"id":"https://openalex.org/keywords/b-cell-non-hodgkin-lymphoma","display_name":"B-cell non-Hodgkin lymphoma","score":0.7149999737739563}],"concepts":[{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.7803056240081787},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.7053321003913879},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.7049881219863892},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.7035568356513977},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6768180727958679},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5052927136421204},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4663117825984955},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.45261651277542114},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4350045323371887},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.413222074508667},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3747580647468567},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.27025073766708374},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.24089542031288147},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.20193538069725037}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-140849","doi":"https://doi.org/10.1182/blood-2020-140849","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-140849","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2982985811","https://openalex.org/W4223554014","https://openalex.org/W4248934506","https://openalex.org/W3182425369","https://openalex.org/W4379981819","https://openalex.org/W4226198876","https://openalex.org/W2115450015","https://openalex.org/W2555882937","https://openalex.org/W2922499299","https://openalex.org/W570755661"],"abstract_inverted_index":{"Mantle":[0],"cell":[1,122,126,152,156,284],"lymphoma":[2,11],"(MCL)":[3],"is":[4,64,117,147,180],"a":[5,181,201,231,380],"rare":[6],"but":[7],"aggressive":[8],"B-cell":[9],"non-Hodgkin's":[10],"that":[12,145,167,246,375],"represents":[13],"6%":[14],"of":[15,85,103,113,131,154,188,199,239,267,283,298,342,363,365,408],"all":[16],"lymphomas":[17],"in":[18,35,55,70,99,119,174,196,210,226,256,273,295,326,334,385,396,405,423,442,453,464,475],"the":[19,101,114,120,129,151,186,195,224,236,294,311,335,361,373,404],"United":[20],"States.":[21],"Recent":[22,89],"therapies":[23,51,63],"including":[24,218,310],"anti-CD20":[25],"antibody":[26,205],"rituximab,":[27,219,301,305],"BTK":[28],"inhibitors,":[29],"and":[30,44,124,159,177,221,287,302,324,337,350,412,416],"BCL-2":[31],"inhibitors":[32],"alone":[33,251],"or":[34,49,209,215,277,368],"combination":[36,211,274],"have":[37,379],"shown":[38],"great":[39],"anti-MCL":[40,254,265],"efficacy.":[41],"However,":[42],"primary":[43,160],"acquired":[45],"resistance":[46,60,78,127,418],"to":[47,61,75,81,318,322,359,419],"one":[48],"multiple":[50],"commonly":[52],"occurs,":[53],"resulting":[54,422],"poor":[56],"clinical":[57,68],"outcome.":[58],"Therefore,":[59],"such":[62,134,270],"currently":[65,357],"an":[66,110,171],"unmet":[67],"challenge":[69],"MCL":[71,87,155,161,175,343],"patients.":[72,88],"Therapeutic":[73],"strategies":[74],"overcome":[76],"this":[77],"holds":[79],"promise":[80],"significantly":[82,292],"improve":[83],"survival":[84],"refractory/relapsed":[86],"studies":[90,355],"showed":[91,393],"Fc":[92],"gamma":[93],"receptors":[94],"(Fc\u03b3Rs)":[95],"play":[96,170],"important":[97,172],"roles":[98],"enhancing":[100],"efficacy":[102,198,297,395,407],"antibody-based":[104,268],"immunotherapy.":[105],"In":[106,223,387],"particular,":[107],"FcgRIIB":[108,146,168,179,248],"(CD32B),":[109],"inhibitory":[111],"member":[112],"Fc\u03b3R":[115],"family,":[116],"implicated":[118],"immune":[121],"desensitization":[123],"tumor":[125,237,243,307],"through":[128],"internalization":[130],"therapeutic":[132,183],"antibodies":[133],"as":[135,230,271,369,390],"rituximab.":[136,351],"Based":[137],"on":[138,150,306],"our":[139],"flow":[140],"cytometry":[141],"analysis,":[142],"we":[143,193,259],"demonstrated":[144],"highly":[148],"expressed":[149],"surface":[153],"lines":[157],"(n=10)":[158],"patient":[162],"samples":[163],"(n=22).":[164],"This":[165,328],"indicates":[166],"may":[169,378],"role":[173],"malignancy":[176],"identifies":[178],"potential":[182],"target":[184],"for":[185],"treatment":[187],"MCL.":[189,386],"To":[190],"address":[191],"this,":[192],"tested":[194],"vivo":[197,227,296,406],"BI-1206,":[200,229],"fully":[202],"humanized":[203],"monoclonal":[204],"targeting":[206,247],"FcgRIIB,":[207],"alone,":[208],"with":[212,275,348,372],"clinically":[213],"approved":[214],"investigational":[216],"drugs":[217],"ibrutinib":[220,276,299,323,336,409],"venetoclax.":[222],"first":[225],"cohort,":[228],"single":[232,370,391],"agent,":[233],"dramatically":[234],"inhibited":[235],"growth":[238,308],"ibrutinib-venetoclax":[240],"dual-resistant":[241,339],"PDX":[242,340],"models,":[244,315],"suggesting":[245],"by":[249],"BI-1206":[250,262,291,345,376,389,402],"has":[252],"high":[253],"activity":[255,266,384],"vivo.":[257,327],"Next,":[258],"assessed":[260],"whether":[261],"can":[263],"boost":[264],"therapy":[269,371],"rituximab":[272,411,415],"venetoclax":[278,303,325,338,349,413],"using":[279],"additional":[280],"mice":[281],"cohorts":[282],"line-derived":[285],"xenograft":[286,289,314],"patient-derived":[288],"models.":[290],"enhanced":[293,403,424],"plus":[300,304,410,414],"inhibition,":[309],"JeKo-1":[312],"derived":[313],"previously":[316],"proven":[317],"be":[319],"partially":[320],"resistant":[321],"tumor-sensitizaton":[329],"effect":[330],"was":[331,346],"further":[332],"confirmed":[333],"models":[341],"where":[344],"combined":[347],"More":[352],"detailed":[353],"mechanistic":[354],"are":[356],"ongoing":[358],"reveal":[360],"mechanism":[362],"action":[364],"BI-1206-based":[366],"combinations":[367],"possibility":[374],"itself":[377],"cytotoxic":[381],"anti-tumor":[382,425],"direct":[383],"conclusion,":[388],"agent":[392],"potent":[394],"overcoming":[397],"ibrutnib-venetoclax":[398],"dual":[399],"resistance.":[400],"Moveover,":[401],"overcomes":[417],"these":[420],"treatments":[421],"effects.":[426],"Disclosures":[427],"Karlsson:":[428],"BioInvent":[429],"International":[430,435,446,457,468],"AB:":[431,436,447,458,469],"Current":[432,437,439,448,450,459,461,470,472],"Employment.":[433],"M\u00e5rtensson:BioInvent":[434],"Employment,":[438,449,460,471],"equity":[440,451,462,473],"holder":[441,452,463,474],"publicly-traded":[443,454,465,476],"company.":[444,455,466,477],"Kovacek:BioInvent":[445],"Teige:BioInvent":[456],"Frend\u00e9us:BioInvent":[467],"Wang:Pulse":[478],"Biosciences:":[479],"Consultancy;":[480,521,524,530,539],"Loxo":[481],"Oncology:":[482,517,541],"Consultancy,":[483,488,499,526,550,558,567,576],"Research":[484,493,496,500,510,514,527,533,536,555,564,573,582],"Funding;":[485,494,497,501,511,515,528,534,537,556,565,574,583],"Kite":[486],"Pharma:":[487,532],"Other:":[489,545,551,560,569,578],"Travel,":[490,546,552,561,570,579],"accommodation,":[491,547,553,562,571,580],"expenses,":[492,554,563,572,581],"BioInvent:":[495],"Juno:":[498],"Beijing":[502],"Medical":[503,586],"Award":[504],"Foundation:":[505],"Honoraria;":[506,508,518,542],"OncLive:":[507],"Verastem:":[509],"Molecular":[512],"Templates:":[513],"Dava":[516],"Guidepoint":[519],"Global:":[520],"Nobel":[522],"Insights:":[523],"Oncternal:":[525],"InnoCare:":[529],"Acerta":[531],"VelosBio:":[535],"MoreHealth:":[538],"Targeted":[540],"OMI:":[543],"Honoraria,":[544,559,568,577],"expenses;":[548],"Celgene:":[549],"AstraZeneca:":[557],"Pharmacyclics:":[566],"Janssen:":[575],"Lu":[584],"Daopei":[585],"Group:":[587],"Honoraria.":[588]},"counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-11-09T00:00:00"}